Trial Profile
Compassionate Use Program For the Treating Severely Ill Patients of COVID-19 With Remdesivir
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 15 Jul 2020
Price :
$35
*
At a glance
- Drugs Remdesivir (Primary)
- Indications COVID 2019 infections; Severe acute respiratory syndrome
- Focus Adverse reactions; Expanded access; Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 10 Jul 2020 According to an Gilead Sciences media release, data from this study were presented at the Virtual COVID-19 Conference as part of the 23rd International AIDS Conference (AIDS 2020: Virtual).
- 10 Jul 2020 Results presented in a Gilead Sciences media release.
- 07 May 2020 According to an Gilead Sciences media release, the Japanese Ministry of Health, Labour and Welfare (MHLW) approval is based on clinical data from the U.S. National Institute of Allergy and Infectious Diseases's global Phase 3 trial, the company's Phase 3 SIMPLE trial in patients with severe manifestations of COVID-19, and available data from company's compassionate use program, including patients in Japan.